Genentech

View All

Signs-and-Symptoms-of-ADHD
Recognising The Warning Signs Of ADHD

The Attention deficit/hyperactivity disorder (ADHD) is a complex neurodevelopmental disorder that affects children and teens. ADHD is mostly recognised during the early school years and can also continue into adulthood. ADHD includes symptoms such as inattentiveness, hyperactivity, and impulsiveness. Often referred...

Find More

Geographic Atrophy Market | GA Market
Mapping The Pipeline Development In The Geographic Atrophy Market

The Geographic atrophy market size is anticipated to increase during the study period 2017–2030 owing to increasing GA prevalence, better understanding of disease pathophysiology, better therapies and pipeline candidates aimed at addressing the disease from its root. Geographic Atrophy (GA) is an advanced form ...

Find More

Alzheimer’s Disease Market | Biogen | Aducanumab | Eisai| Biogen | Aducanumab | Eisai |
Can Aducanumab Solve the Puzzle Of Alzheimer’s?

Alzheimer's Disease Market finally witnessed the approval of standard therapy, Aducanumab, by Biogen. What impact does it hold for the future? Demographic or population ageing is a global and dominant phenomenon of the 21st century. Different geographies are experiencing population ageing at different rates. As ...

Find More

Alzheimer’s-Disease-Market-Scenario
An Ageing Population and Upcoming Therapies: What is shaping the Alzheimer’s Disease Market Scenario?

The ageing population is a global phenomenon. According to the UN’s “World Population Prospects 2019” by 2100, the world’s population is projected to reach approximately 10.9 billion. Moreover, between 2020 and 2100, the number of people ages 80 and older is expected to increase from 146 million to 881 million. ...

Find More

Egg Allergy Market
Egg Allergy Market: Second most common food allergy but no approved therapy

Hen’s egg allergy is the second most common type of allergy after cow’s milk. In infants and young children, Egg poses as one of the most vital allergens degrading the quality of life.  As per estimates, as many as 2 per cents of children are allergic to eggs. However, around 70% of these children are fortunate ...

Find More

Peanut allergy
FDA is reviewing a dangerous way to treat Peanut Allergy

Peanut allergies (PA) are the most common and severe type of food allergies in children. Even a small fragment of this legume to an allergic person can result in permanent brain damage.  The prevalence rate of the Peanut allergy, over the past two decades, has tripled. According to DelveInsight, total prevalen...

Find More

Systemic sclerosis
FDA approves Ofev for interstitial lung disease

Recently, the US FDA has approved a new drug therapy to treat adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. Ofev (nintedanib) capsules, the drug developed by Boehringer Ingelheim Pharmaceuticals, has shown efficacy in slowing down the rate of decline in pul...

Find More

Notizia 11 june
Notizia

Lilly tests the efficacy of Tirzepatide-a novel dual GIP, GLP-1 agonist Eli Lilly is planning to test its diabetes drug Tirzepatide in a phase 2b Non-Alcoholic Steatohepatitis (NASH) trial. Tirzepatide, also known as LY3298176, has been excellent in reducing body weight and blood sugar in patients with poorly co...

Find More

Genentech remunerates Xencor; XPrize upraises fund; GSK gambles

Genentech remunerates Xencor USD 120 Million for global rights Genentech has remunerated USD 120 million upfront to have global rights to IL-15 cytokine therapeutics in preclinical development at Xencor. Xencor is pursuing IL-15, an immune signaling protein, contemplating that it can stimulate natural...

Find More

Hot flashes
Notizia

TherapeuticsMD bags FDA approval for hormone therapy The FDA has nodded hormone therapy of TherapeuticsMD for hot flashes that are associated with menopause. Bijuva is an oral treatment that contains molecularly identical (bio-identical) versions of the hormones estradiol and progesterone for menopausal women with a...

Find More